In Q1 2025, Deerfield Management held 92 positions worth $3.8B. They initiated 18 new positions and exited 536. Their largest holding was NUVL ($1.3B). Portfolio value shrank -5.4% versus the prior quarter.
Frequently asked questions
What stocks did Deerfield Management own in Q1 2025?
Deerfield Management held 92 biotech stocks in their 13F portfolio in Q1 2025. Their top positions include NUVL, VTRS, NBIX, OSCR, SPRY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deerfield Management's portfolio worth in Q1 2025?
Deerfield Management's tracked biotech portfolio was worth $3.8B across 92 positions, with total assets under management of approximately $16B. Portfolio values are based on 13F filings with the SEC.
What did Deerfield Management buy in Q1 2025?
Deerfield Management initiated 18 new positions in Q1 2025, including PFE, IMCR, PRAX, CERT, BEAM and 13 more. They also increased 37 existing positions.
What did Deerfield Management sell in Q1 2025?
Deerfield Management fully exited 536 positions in Q1 2025, including RILYZ, WRB-PH, CGBD, MRNA, MET-PF and 531 more. They also trimmed 16 existing positions.
Is Deerfield Management a biotech fund?
Multi-strategy healthcare fund with one of the longest track records in the space. Deerfield invests across public equity, private equity, structured credit, and royalties in healthcare. Known for creative financing structures and deep industry relationships across pharma and biotech.
Want AI analysis, insider signals, and catalyst overlays for Deerfield Management?
View latest Deerfield Management portfolio →